Doximity's stock jumped as much as 105% in premarket trading on August 7, 2026, after the company raised its full-year revenue and profit outlook, fueled by a tenfold increase in its AI scribe usage and a first-place finish in an independent clinical AI safety study (Tech Times).

The twin announcements arrived alongside Doximity's fiscal 2027 first-quarter earnings release, which had been scheduled for August 6, 2026 (Doximity Investor Relations). The same day, the company said its clinical AI tool outranked OpenEvidence and other frontier AI models in an independent Stanford-Harvard study evaluating the safety of clinical AI systems (Doximity Press).

For context, an AI scribe is software that listens to a doctor-patient conversation and automatically drafts clinical notes. A tenfold jump in usage means doctors are not merely testing the tool in pilot programs — they appear to be adopting it in their daily workflows. That matters for Doximity because the company's revenue depends on keeping physicians engaged on its platform, which in turn attracts pharmaceutical marketing dollars.

The safety study result adds a different kind of boost. Clinical AI tools face a high bar for trust: if doctors don't believe a tool is safe, they won't use it. Outperforming well-funded competitors in an independent academic evaluation gives Doximity a credibility claim that most vendors in this space cannot match, since many rely on their own internal benchmarks.

The broader context here is that digital health AI has faced a persistent question: can clinical-grade tools turn into durable, growing revenue? Doximity's announcement bundles two answers in one news cycle — real adoption (tenfold usage growth) and independent validation (topping a Stanford-Harvard safety study). The market's sharp reaction suggests investors are weighing both signals heavily.

A 105% premarket move reflects a repricing of both near-term fundamentals and the story around Doximity's AI position. The guidance raise ties the surge to actual expected revenue and profit rather than sentiment alone. The safety study extends the investment case into a competitive moat argument: if Doximity's clinical AI is independently verified as safer than alternatives, doctors may be reluctant to switch, and usage patterns could compound from there.

Whether the premarket gap holds once regular trading begins will depend on the specifics of the raised guidance, the Q1 earnings details, and what management says about whether AI scribe growth can continue at this pace. Premarket moves of this size often attract profit-taking at the opening bell, so the gap between the early 105% surge and the closing price will offer the first real read on how much conviction backs the repricing.

The competitive angle is worth watching. OpenEvidence and frontier AI models are serious competitors, and outranking them in a safety evaluation is no small feat. If the Stanford-Harvard methodology holds up under scrutiny, Doximity's result could pressure competitors to strengthen their own safety validation efforts. That said, a single study — even one backed by prestigious institutions — is one data point. Replication across additional institutions and clinical areas will determine whether this positioning claim hardens into a lasting advantage.